
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate Inc has significantly strengthened its balance sheet, which positions the company favorably for future growth and market opportunities. The positive outcome of a Phase 3 study for CTx-1301, evidenced by an industry-leading average effect size of 1.79 compared to the 0.73 average of marketed ADHD drugs, bolsters its potential market competitiveness. Additionally, the increased probability of approval for CTx-1301 to 75%, supported by the FDA's recognition of leveraging existing data, underscores the promising outlook for Cingulate's innovative product pipeline.
Bears say
Cingulate Inc faces significant risks that contribute to a negative outlook on its stock, primarily stemming from potential delays in the development and regulatory approval process for its product CTx-1301. The company may encounter challenges such as slower market uptake and lower-than-expected penetration rates for CTx-1301 in the ADHD segment, along with partnership risks related to its relationship with Indegene. Additionally, there is a looming threat of dilution in the near to medium term, further complicating the company’s financial position amidst a mature ADHD market environment reflected by a 12% discount rate.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares